TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update

Core Points - TG Therapeutics, Inc. will hold a conference call on March 3, 2025, at 8:30 AM ET to discuss the fourth quarter and full year 2024 results and provide a business outlook for 2025 [1] - The call will be hosted by Michael S. Weiss, Chairman and CEO of TG Therapeutics [1] - A press release detailing the financial results will be issued prior to the conference call [3] Company Overview - TG Therapeutics is a fully integrated, commercial stage biopharmaceutical company focused on developing and commercializing novel treatments for B-cell diseases [4] - The company has received FDA approval for BRIUMVI® (ublituximab-xiiy) for treating adult patients with relapsing forms of multiple sclerosis [4] - BRIUMVI has also been approved by the European Commission and the Medicines and Healthcare Products Regulatory Agency for similar indications in Europe and the UK [4]